Which has stronger earnings and valuation, VINC or AMPE?

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A

Is VINC or AMPE more profitable?

Ampio Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Vincerx Pharma N/A -248.33% -132.73% Ampio Pharmaceuticals N/A N/A N/A

Is PTPI or VINC more profitable?

Petros Pharmaceuticals' return on equity of -78.22% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Petros Pharmaceuticals N/A -78.22% -23.50% Vincerx Pharma N/A -248.33% -132.73%

Do analysts rate VINC or CARM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vincerx Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, SCPS or VINC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scopus BioPharma N/A N/A -$11.61M N/A N/A Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A

Is SCPS or VINC more profitable?

Scopus BioPharma's return on equity of 0.00% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Scopus BioPharma N/A N/A N/A Vincerx Pharma N/A -248.33% -132.73%

Is VINC or SYRS more profitable?

Vincerx Pharma's return on equity of -248.33% beat Syros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Vincerx Pharma N/A -248.33% -132.73% Syros Pharmaceuticals N/A -3,369.56% -97.04%

Vincerx Pharma (VINC) Competitors

$0.01 0.00 (0.00%)

As of 09/2/2026

Compare

VINC vs. AMPE, PTPI, CARM, SCPS, and SYRS

Should you buy Vincerx Pharma stock or one of its competitors? Vincerx Pharma's main competitors and comparable companies include Ampio Pharmaceuticals (AMPE), Petros Pharmaceuticals (PTPI), Carisma Therapeutics (CARM), Scopus BioPharma (SCPS), and Syros Pharmaceuticals (SYRS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Vincerx Pharma compare to Ampio Pharmaceuticals?

Vincerx Pharma (NASDAQ:VINC) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Ampio Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-248.33%	-132.73%
Ampio Pharmaceuticals	N/A	N/A	N/A

44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by company insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A

Vincerx Pharma has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, meaning that its share price is 496% more volatile than the broader market.

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Vincerx Pharma	Neutral
Ampio Pharmaceuticals	Neutral

Summary

Vincerx Pharma and Ampio Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and Vincerx Pharma (NASDAQ:VINC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Petros Pharmaceuticals' return on equity of -78.22% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Vincerx Pharma	N/A	-248.33%	-132.73%

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Vincerx Pharma	Neutral

Petros Pharmaceuticals has higher revenue and earnings than Vincerx Pharma. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.03	-$8.16M	-$0.36	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Petros Pharmaceuticals has a beta of 1.94, suggesting that its share price is 94% more volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

Summary

Petros Pharmaceuticals beats Vincerx Pharma on 6 of the 9 factors compared between the two stocks.

How does Vincerx Pharma compare to Carisma Therapeutics?

Vincerx Pharma (NASDAQ:VINC) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vincerx Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Vincerx Pharma has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-248.33%	-132.73%
Carisma Therapeutics	-254.28%	N/A	-192.17%

44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Vincerx Pharma has higher earnings, but lower revenue than Carisma Therapeutics. Vincerx Pharma is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company	Overall Sentiment
Vincerx Pharma	Neutral
Carisma Therapeutics	Neutral

Vincerx Pharma has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of -9.01, indicating that its stock price is 1,001% less volatile than the broader market.

Summary

Carisma Therapeutics beats Vincerx Pharma on 6 of the 11 factors compared between the two stocks.

How does Vincerx Pharma compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Vincerx Pharma (NASDAQ:VINC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company	Overall Sentiment
Scopus BioPharma	Neutral
Vincerx Pharma	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

Scopus BioPharma has a beta of -0.19, suggesting that its stock price is 119% less volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market.

44.0% of Vincerx Pharma shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Scopus BioPharma's return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scopus BioPharma	N/A	N/A	N/A
Vincerx Pharma	N/A	-248.33%	-132.73%

Summary

Scopus BioPharma and Vincerx Pharma tied by winning 3 of the 6 factors compared between the two stocks.

How does Vincerx Pharma compare to Syros Pharmaceuticals?

Vincerx Pharma (NASDAQ:VINC) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Vincerx Pharma's return on equity of -248.33% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-248.33%	-132.73%
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%

Vincerx Pharma has higher earnings, but lower revenue than Syros Pharmaceuticals. Vincerx Pharma is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A
Syros Pharmaceuticals	$386K	0.03	-$164.57M	-$3.03	N/A

Vincerx Pharma has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market.

44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Syros Pharmaceuticals had 1 more articles in the media than Vincerx Pharma. MarketBeat recorded 1 mentions for Syros Pharmaceuticals and 0 mentions for Vincerx Pharma. Vincerx Pharma's average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Vincerx Pharma	Neutral
Syros Pharmaceuticals	Neutral

Summary

Syros Pharmaceuticals beats Vincerx Pharma on 6 of the 10 factors compared between the two stocks.

Get Vincerx Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VINC vs. The Competition

Export

Metric	Vincerx Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$69K	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	0.00	787.27	273.29	25.25
Price / Sales	N/A	754.88	623.67	97.64
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	0.00	12.33	12.92	6.14
Net Income	-$40.16M	$2.82B	$3.47B	$349.01M
7 Day Performance	N/A	2.60%	0.60%	-0.27%
1 Month Performance	N/A	6.96%	5.72%	0.68%
1 Year Performance	N/A	9.45%	25.33%	14.84%

Vincerx Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VINC Vincerx Pharma	N/A	$0.01 flat	N/A	N/A	$69K	N/A	N/A	60
AMPE Ampio Pharmaceuticals	N/A	$0.18 flat	N/A	N/A	$208K	N/A	N/A	20
PTPI Petros Pharmaceuticals	N/A	$0.00 -6.0%	N/A	-82.1%	$146K	$5.11M	N/A	20	Gap Down
CARM Carisma Therapeutics	0.3354 of 5 stars	$0.00 -30.0%	N/A	-99.8%	$29K	$10.77M	0.00	20	Gap Down
SCPS Scopus BioPharma	N/A	$0.00 flat	N/A	N/A	$17K	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VINC) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vincerx Pharma (VINC) Competitors

VINC vs. AMPE, PTPI, CARM, SCPS, and SYRS

How does Vincerx Pharma compare to Ampio Pharmaceuticals?

Summary

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Summary

How does Vincerx Pharma compare to Carisma Therapeutics?

Summary

How does Vincerx Pharma compare to Scopus BioPharma?

Summary

How does Vincerx Pharma compare to Syros Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VINC vs. The Competition

Vincerx Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vincerx Pharma (VINC) Competitors

VINC vs. AMPE, PTPI, CARM, SCPS, and SYRS

How does Vincerx Pharma compare to Ampio Pharmaceuticals?

Is VINC or AMPE more profitable?

Do insiders and institutionals hold more shares of VINC or AMPE?

Which has stronger earnings and valuation, VINC or AMPE?

Which has more risk & volatility, VINC or AMPE?

Does the media favor VINC or AMPE?

Summary

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Is PTPI or VINC more profitable?

Does the media prefer PTPI or VINC?

Which has higher valuation and earnings, PTPI or VINC?

Do institutionals & insiders have more ownership in PTPI or VINC?

Which has more volatility & risk, PTPI or VINC?

Summary

How does Vincerx Pharma compare to Carisma Therapeutics?

Do analysts rate VINC or CARM?

Is VINC or CARM more profitable?

Do institutionals & insiders believe in VINC or CARM?

Which has better earnings and valuation, VINC or CARM?

Does the media prefer VINC or CARM?

Which has more risk and volatility, VINC or CARM?

Summary

How does Vincerx Pharma compare to Scopus BioPharma?

Does the media prefer SCPS or VINC?

Which has better valuation & earnings, SCPS or VINC?

Which has more volatility & risk, SCPS or VINC?

Do insiders and institutionals hold more shares of SCPS or VINC?

Is SCPS or VINC more profitable?

Summary

How does Vincerx Pharma compare to Syros Pharmaceuticals?

Is VINC or SYRS more profitable?

Which has preferable earnings and valuation, VINC or SYRS?

Which has more risk and volatility, VINC or SYRS?

Do institutionals & insiders hold more shares of VINC or SYRS?

Does the media refer more to VINC or SYRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VINC vs. The Competition

Vincerx Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools